The scientific logic rests on a phenomenon called immunometabolic reprogramming. Microglia, the resident innate immune cells of the central nervous system, normally run on mitochondrial oxidative phosphorylation, an efficient mode of energy generation that sustains their quiet surveillance of the brain. Confronted with amyloid-β aggregates, oxidative stress, and persistent inflammatory signals, however, they shift toward aerobic glycolysis, the rapid but wasteful glucose-burning program familiar from cancer cells and acutely activated immune cells. Useful for a short burst of defense, this metabolic posture becomes destructive when it hardens into a permanent state, locking microglia into a pro-inflammatory phenotype characterized by excessive reactive oxygen species, crippled respiration, and amplified cytokine output. At the center of the malfunction sits a three-part signaling circuit. AMPK acts as the cell’s fuel gauge, preserving mitochondrial homeostasis and restraining inflammation. mTOR integrates nutrient and growth signals to drive anabolic, glycolytic metabolism, while HIF-1α, which mTOR activates, switches on the transcription of glycolytic enzymes and glucose transporters. In the Alzheimer’s brain, AMPK activity falters even as mTOR and HIF-1α remain stubbornly switched on, and the resulting inflammation-metabolism loop feeds on itself.

Rather than blocking a single inflammatory molecule, the team drew on the traditional Chinese medicine principle of “BuShen HuoXue,” tonifying the kidney and activating blood circulation, long applied to disorders of cognitive decline. From that framework they selected two compounds: icaritin, a flavonoid from Epimedium reported to support energy sensing and mitochondrial health, and tanshinone IIA, a diterpene from Salvia miltiorrhiza with documented anti-neuroinflammatory activity. Network pharmacology suggested the pair converges on AMPK and mTOR signaling, but both molecules are handicapped as drugs: they dissolve poorly in water, cross the blood-brain barrier inefficiently, and never reach meaningful concentrations inside diseased microglia. The researchers’ answer, developed by Ge Zhang, Ying Yang, Xue-tao Li, Yang Yu, and colleagues, was to encapsulate them within nanoparticles built from Panax notoginseng polysaccharide, a biocompatible, biodegradable macromolecule with intrinsic antioxidant and immunomodulatory activity that the team treated not as an inert wrapper but as a functional component of the therapy itself.

The resulting platform, named KPBIT@NPs, is a small feat of materials chemistry. The researchers first grafted 4-carboxyphenylboronic acid pinacol ester, or CPBA, onto the polysaccharide, adding hydrophobic domains that let the polymer chains self-assemble into spherical particles in water. They then attached KLVFFAED, a peptide taken from the amyloid-β sequence itself, exploiting its ability to engage RAGE, the receptor for advanced glycation end products, which is upregulated in Alzheimer’s disease and participates in amyloid transport across the blood-brain barrier. Proton nuclear magnetic resonance and Fourier transform infrared spectroscopy confirmed each modification step, and systematic variation of the CPBA feed ratio revealed a non-linear relationship between grafting density and assembly behavior, with a grafting degree of 8.95 percent giving the lowest critical aggregation concentration while preserving water solubility. The final formulation formed uniform, near-spherical particles about 79 nanometers in diameter with a near-neutral surface charge, encapsulating 92 percent of the icaritin and 87 percent of the tanshinone IIA and remaining stable in serum for two weeks.

The most elegant feature is the particles’ responsiveness to the disease environment. The phenylboronic ester bonds anchoring CPBA to the polysaccharide are cleaved by reactive oxygen species, which accumulate in the inflamed Alzheimer’s brain. When the nanoparticles were exposed to hydrogen peroxide in the laboratory, transmission electron microscopy showed them fragmenting, and drug release accelerated in a concentration-dependent manner from mild oxidative stimulation to high oxidative challenge; in neutral buffer, the cargo stayed locked inside. To test delivery, the team built a blood-brain barrier model with bEnd.3 endothelial cells cultured in Transwell chambers above BV2 microglia, then degraded the barrier with amyloid-β and lipopolysaccharide to mimic disease conditions while preserving measurable barrier integrity, verified by transendothelial electrical resistance, sodium fluorescein permeability, and tight-junction staining. KLV-modified nanoparticles crossed the injured barrier far more efficiently than unmodified versions and were taken up more avidly by the microglia below, an advantage that collapsed when cells were pretreated with the RAGE inhibitor FPS-ZM1. In living animals, near-infrared imaging showed the modified particles circulating for up to 72 hours and accumulating in APP/PS1 mouse brain well above non-targeted controls.

Inside microglia, the two drugs proved better together than apart. Using the SynergyFinder platform, the team screened combinations of free icaritin and tanshinone IIA in BV2 microglia injured by amyloid-β and lipopolysaccharide and identified a 1:1 molar ratio as optimal, with synergy scores above the threshold for significant cooperation. Nanoparticles loaded at that ratio outperformed single-drug and non-targeted formulations across every assay. They cut intracellular reactive oxygen species, lowered malondialdehyde, a marker of lipid peroxidation, and raised glutathione and catalase. They suppressed interleukin-6, interleukin-1β, and tumor necrosis factor-α while boosting the reparative markers arginase-1 and interleukin-10. Flow cytometry and immunofluorescence tracked a phenotypic migration from the pro-inflammatory M1 state, marked by CD86, toward the restorative M2 state, marked by CD206, and JC-1 staining showed damaged mitochondrial membrane potential substantially restored. Conditioned medium from treated microglia, transferred onto HT22 neurons, reduced neuronal apoptosis and oxidative stress, demonstrating that reprogrammed microglia become actively protective toward their neighbors.

The mechanism was then interrogated at the level of signaling proteins. Western blotting revealed that stressed microglia carried a depressed p-AMPK/AMPK ratio alongside elevated p-mTOR/mTOR and HIF-1α, the biochemical signature of a cell stuck in glycolytic overdrive, and KPBIT@NPs reversed all three markers. Downstream metabolic enzymes told the same story: expression of PFKFB3, a rate-limiting glycolytic regulator, fell, while inhibitory phosphorylation of PDHE1α declined, freeing pyruvate to enter the tricarboxylic acid cycle. Real-time flux analysis measured a drop in the extracellular acidification rate, a proxy for glycolysis, and a rise in the oxygen consumption rate, the direct readout of mitochondrial respiration, with basal respiration, ATP production, maximal respiration, and spare respiratory capacity all climbing. The glycolytic enzyme LDHA dimmed while ATP5A, a core subunit of mitochondrial ATP synthase, brightened. Crucially, the AMPK inhibitor Compound C blunted these effects and the mTOR activator MHY1485 reversed them, establishing that the AMPK-mTOR/HIF-1α axis is not merely correlated with the therapeutic effect but required for it.

Computational analyses reinforced the drug pairing. The team assembled a network spanning 48 active compounds from Epimedium and Salvia miltiorrhiza, 736 predicted drug targets, and 16,820 Alzheimer’s-related genes, converging on 688 shared targets. Pathway enrichment placed AMPK and mTOR signaling among the most significantly represented routes, with HIF-1α emerging as a hub node, and molecular docking with AutoDock Vina returned favorable binding energies for both compounds against both proteins: tanshinone IIA bound AMPK at −9.70 kilocalories per mole and mTOR at −8.83, while icaritin registered −8.17 and −7.17 respectively, with hydrogen bonding and hydrophobic contacts stabilizing the interactions. The computations suggest that this classical herb pair achieves, through complementary chemistry, precisely the dual regulation that Alzheimer’s pathology disrupts.

In APP/PS1 mice, the cellular effects translated into behavior and brain structure. Treated animals located the hidden platform faster in the Morris water maze, spent more time in the target quadrant, crossed the platform location more often, and built more coherent nests, a standard measure of daily function. Amyloid plaque burden in cortex and hippocampus shrank, Nissl staining revealed healthier neuronal layers, NeuN staining indicated greater neuronal survival, and Golgi staining showed dendritic trees with restored length and branching. Transmission electron microscopy of hippocampal tissue found mitochondria with intact cristae and membranes where model mice carried swollen, disrupted organelles. Whole-brain biochemical assays completed the picture: activities of the tricarboxylic acid cycle enzymes isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, and succinate dehydrogenase, along with respiratory chain complexes I through V and total ATP content, all rebounded, while lactate, pyruvate, hexokinase, and lactate dehydrogenase, the fingerprints of glycolytic accumulation, receded. Markers of astrocyte and microglial activation, GFAP and IBA-1, fell, and co-staining confirmed the CD86-to-CD206 phenotypic flip within IBA-1-positive microglia in the brain itself.

Safety data were reassuring at this stage: hemolysis rates stayed below accepted thresholds, organ histology appeared normal, blood counts were unremarkable, and serum cytokines showed no peripheral inflammatory activation. The authors are candid about limitations. Their brain metabolic measurements relied on bulk homogenates that cannot separate microglial metabolism from that of neurons or astrocytes, direct intracerebral colocalization of the nanoparticles was not obtained, and long-term biodistribution, biodegradation, and clearance remain unexamined. They propose a three-stage follow-up combining single-cell multi-omics with spatial metabolic imaging, extracellular flux and isotope-tracing assays on purified primary microglia, and microglia-specific blockade of the AMPK-mTOR/HIF-1α axis to establish cell-autonomous causality. Even with those caveats, the study delivers a proof of concept with wider implications: a natural polysaccharide can be engineered into a carrier that is not passive cargo space but an active participant in therapy, delivering two synergistic plant compounds to the exact immune cells whose metabolic derailment helps drive neurodegeneration. If the framework survives more advanced preclinical testing, it could extend beyond Alzheimer’s disease to other disorders, from Parkinson’s disease to stroke, in which inflammation and metabolism fail together.

The molecular landscape of glioblastoma is extraordinarily complex. Tumours that appear similar under the microscope can be driven by very different combinations of genetic alterations, while distinct regions within the same tumour may carry different mutations and signalling programs. This intratumoural heterogeneity means that a drug aimed at one mutation may destroy only a fraction of the cancer. The remaining cells can expand, repopulate the tumour and acquire additional resistance mechanisms. Glioblastoma cells also display considerable plasticity, changing their state in response to treatment, oxygen levels, immune signals and interactions with surrounding brain tissue. As a result, a therapy that works in one cellular state may become ineffective when the tumour shifts into another.

Receptor tyrosine kinases remain among the most prominent targets under investigation. These cell-surface proteins transmit signals controlling proliferation, survival, migration and metabolism. Abnormal activation of receptors such as epidermal growth factor receptor, platelet-derived growth factor receptors and vascular endothelial growth factor receptors can push glioblastoma cells into continuous growth. However, blocking a single receptor has often failed because signalling networks are highly redundant. A tumour may activate a parallel receptor, increase downstream signalling or use alternative pathways to maintain survival. The review therefore emphasizes the importance of understanding pathway activity rather than relying solely on the presence of a single genetic alteration. Functional profiling could reveal which signalling circuits remain essential after treatment begins.

Downstream intracellular proteins offer another set of potential targets. The PI3K–AKT–mTOR pathway, the RAS–RAF–MEK–ERK cascade and other signalling networks integrate information from growth-factor receptors and the tumour microenvironment. In glioblastoma, these pathways can be activated through mutations, gene amplification, loss of tumour suppressors or non-genetic mechanisms. Inhibiting them is technically difficult because the same pathways are needed by normal cells, creating toxicity concerns, while feedback loops can rapidly restore signalling after treatment. Effective drug combinations may need to block several nodes at once, but combination therapy increases the risk of adverse effects and complicates clinical testing. The most promising strategy may involve identifying a tumour’s dominant or “master” kinase state and matching it with drugs that suppress the pathway on which its cells are functionally dependent.

Cell-cycle dysregulation is another defining feature of glioblastoma. Alterations affecting cyclin-dependent kinases, retinoblastoma protein, p53-related responses and other cell-cycle regulators allow malignant cells to divide despite DNA damage and abnormal growth signals. Drugs targeting cyclin-dependent kinases or related checkpoints could, in principle, force tumour cells into arrest or increase their sensitivity to radiation and chemotherapy. Yet cell-cycle inhibitors must distinguish between rapidly dividing cancer cells and essential normal tissues. Moreover, glioblastoma contains slow-cycling and stem-like populations that may survive therapies designed primarily to eliminate proliferating cells. These resistant reservoirs can later re-enter the cell cycle, contributing to recurrence. The review presents synthetic-lethal approaches as a way to address this problem by targeting weaknesses that become critical only when a particular tumour suppressor or repair pathway is already lost.

Synthetic lethality occurs when disabling either of two genes or pathways alone is tolerated, but disabling both is fatal to the cell. This principle has transformed treatment strategies in some cancers and may be especially valuable in glioblastoma, where genome-maintenance systems are frequently disrupted. Tumours with defects in DNA repair may become unusually dependent on backup repair mechanisms, replication-stress responses or checkpoint proteins. Drugs that inhibit these compensatory systems could selectively damage cancer cells while sparing healthier cells with intact repair capacity. The approach is not without obstacles: glioblastoma cells can vary in their repair defects, and resistance may emerge through restoration of the damaged pathway or activation of alternative mechanisms. Careful molecular selection and repeated tumour monitoring will therefore be essential.

New therapeutic concepts are also expanding beyond conventional kinase inhibition. Researchers are examining strategies aimed at genome integrity, telomere maintenance and epigenetic regulation. Telomeres protect chromosome ends, but cancer cells often reactivate telomerase or use alternative mechanisms to maintain unlimited replicative potential. Blocking these systems could gradually undermine tumour growth, although the delayed action of telomere-directed treatments may limit their usefulness in rapidly progressing disease. Epigenetic drugs seek to alter gene expression without changing the DNA sequence, potentially reversing malignant cell states or restoring sensitivity to other therapies. Because epigenetic regulation is dynamic and closely linked to cellular identity, these agents could be used to target the plasticity that allows glioblastoma cells to escape treatment.

Drug delivery remains one of the most formidable barriers. The blood–brain barrier is formed by tightly connected endothelial cells, specialized transport systems and supporting pericytes and astrocytes. It protects neural tissue from toxins, but also prevents many anticancer drugs from reaching therapeutic concentrations in the tumour. Glioblastoma can locally disrupt the barrier, yet this disruption is uneven, and infiltrating cells may reside in areas where drug exposure is minimal. The review discusses focused ultrasonography as one method for temporarily opening the barrier, potentially allowing drugs to enter selected regions. Convection-enhanced delivery takes a different approach by infusing treatment directly into tumour tissue under pressure. Other strategies include modifying molecules to improve brain penetration, avoiding active efflux pumps that expel drugs from the central nervous system and developing delivery vehicles that transport therapeutic payloads more selectively.

The review also highlights antibody–drug conjugates and theranostics as emerging modalities. Antibody–drug conjugates combine a targeting antibody with a potent cytotoxic compound, allowing the drug to be carried toward cells displaying a chosen surface marker. Their success in glioblastoma will depend on whether that marker is sufficiently abundant across the tumour and accessible from the bloodstream. Theranostic platforms unite diagnosis and treatment, enabling clinicians to identify molecular targets, deliver a therapeutic agent and monitor its distribution or biological effect. These approaches may become more powerful when combined with multiregional sampling. Instead of analysing a single surgical specimen, clinicians could compare samples from different tumour zones to distinguish early, shared “truncal” alterations from later, region-specific changes. Targeting truncal dependencies could reduce the likelihood that untreated subclones survive.

Genomic complexity is further intensified by extrachromosomal DNA, or ecDNA, circular DNA elements that exist outside normal chromosomes. These structures can carry amplified oncogenes, sometimes at very high copy numbers, and can be unevenly distributed among tumour cells. Their inheritance during cell division is less predictable than that of chromosomal DNA, allowing cancer populations to rapidly change the number and arrangement of oncogenic copies under therapeutic pressure. EcDNA may therefore help explain why glioblastomas can become resistant with extraordinary speed. Liquid biopsies, using tumour-derived DNA, RNA or other molecules found in blood or cerebrospinal fluid, could provide a less invasive way to track these changes. Although technical and sensitivity challenges remain, serial monitoring might reveal emerging resistance before it becomes visible on imaging.

Future clinical trials may need to move beyond the traditional model in which one drug is tested against an entire disease category. Pathway-based classification could group patients according to active biological programs rather than tumour appearance alone, while master kinase mapping could identify the dominant signalling dependencies operating in each tumour. Adaptive trials could then modify treatment as molecular data change, testing rational combinations in smaller, genetically defined populations. Such designs may be especially important for glioblastoma because the disease evolves during therapy and differs substantially from one patient to another. The overall message of the review is cautiously optimistic: progress will require more than discovering additional mutations. It will depend on integrating spatial tumour profiling, functional biology, advanced delivery systems, dynamic monitoring and therapies capable of confronting the tumour’s shifting cellular states.

Subject of Research: Targetable molecular alterations and therapeutic strategies in glioblastoma.

Article Title: Exploring the landscape of targetable alterations in patients with glioblastoma.

Article References: Aquilanti, E., Touat, M., French, P. et al. “Exploring the landscape of targetable alterations in patients with glioblastoma.” Nature Reviews Clinical Oncology (2026). https://doi.org/10.1038/s41571-026-01190-7

Image Credits: AI Generated

DOI: 10.1038/s41571-026-01190-7

Keywords: Glioblastoma, targeted therapy, intratumoural heterogeneity, blood–brain barrier, receptor tyrosine kinases, synthetic lethality, extrachromosomal DNA, liquid biopsy, epigenetic therapy, theranostics.

The blood-brain barrier, a highly selective semipermeable membrane of endothelial cells, protects the brain by filtering out potentially harmful substances circulating in the bloodstream while allowing only essential nutrients to pass. Unfortunately, this protective barrier also blocks many therapeutic agents, making effective drug delivery to brain tumors notably difficult. In their study published in the Journal of Controlled Release, the researchers innovatively engineered lipid nanoparticles to carry therapeutic mRNA molecules and coat them with a sugar molecule—mannose—that cleverly exploits natural nutrient transport mechanisms to cross the BBB.

Their strategy harnesses the brain endothelium’s GLUT1 transporter, a protein embedded in the blood vessel lining dedicated to the uptake of glucose, the brain’s chief energy source. Mannose, a sugar structurally similar to glucose, can also be recognized and transported by GLUT1. By densely coating lipid nanoparticles with mannose chemically linked to cholesterol, the researchers drastically improved the particles’ ability to hijack this transporter and slip through the blood-brain barrier. This molecular camouflage represents a novel breakthrough that elevates the efficiency of nanoparticle transport into the central nervous system.

Inside these mannose-coated nanoparticles, the scientists encapsulated messenger RNA encoding PTEN, a tumor suppressor protein that is commonly lost or mutated in glioblastoma cells. PTEN plays a critical role in regulating cellular growth and preventing malignancy. By restoring PTEN expression, the therapeutic mRNA triggers mechanisms that inhibit tumor proliferation and promote cancer cell death. To protect the fragile mRNA payload during delivery, they also incorporated a cationic cholesterol derivative, which enhances encapsulation stability and ensures the therapeutic’s integrity upon reaching its target.

This dual-targeting approach proved strikingly effective in a rigorous mouse model of glioblastoma. Treated animals experienced a 50% increase in median survival time compared to controls, a remarkable milestone given glioblastoma’s notorious resistance to conventional therapies. Tumors showed significant shrinkage after repeated dosing, and importantly, there was no detectable toxicity to other organs. The approach combines specificity and potency, minimizing collateral damage—a frequent limitation of systemic cancer treatments.

The researchers highlight that glioblastoma cells exhibit elevated GLUT1 expression—approximately threefold higher than normal brain tissue—which facilitates selective nanoparticle accumulation in tumor regions after crossing the blood-brain barrier. This metabolic reprogramming of glioblastoma not only supports tumor growth but also inadvertently provides a therapeutic window for targeted delivery systems exploiting glucose transport pathways. This innovative exploitation of tumor physiology underscores a shift toward smarter, more precise nanomedicine treatments.

Though glioblastoma is relatively rare with an incidence rate of 3.19 per 100,000 people in the United States, its devastating prognosis and rapid progression necessitate urgent intervention strategies. Affecting men more frequently than women and typically diagnosed around age 64, glioblastoma’s five-year survival rate plunges below 5%. The urgent clinical need drives continued research into novel therapies capable of improving outcomes and quality of life for this vulnerable population.

The multidisciplinary study team included Vincent Cataldi, Vladislav Grigoriev, Neera Yadav, Tetiana Korzun, Chao Wang, and Adam Alani, alongside the lead investigators. Their collective expertise spanned nanotechnology, pharmacology, molecular biology, and oncology, enabling the comprehensive design and testing of these multifunctional nanoparticles. Funding and support came from prestigious bodies including the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Research Foundation of Korea.

This study’s success establishes a promising platform for advancing mRNA-based therapeutics beyond glioblastoma. The foundational innovation—using a single ligand, mannose, to achieve dual targeting of crossing the BBB and preferential tumor accumulation—could be adapted for other neurological diseases requiring delivery of genetic medicine to the brain. The ability to deliver functional mRNA payloads securely and efficiently represents an exciting frontier in personalized medicine.

Future research will undoubtedly focus on scaling up this approach, optimizing dosing regimens, and eventually translating these findings into clinical trials in humans. Safety profiles observed in animal models are encouraging, but further studies are essential to fully understand long-term effects, potential immune responses, and therapeutic durability. The OSU team’s pioneering work paves the way for new hope in the relentless battle against a cancer that has defied treatment for decades.

In summary, this novel nanomedicine strategy addresses the fundamental challenges that have long hindered glioblastoma therapy: surmounting the blood-brain barrier and selectively delivering tumor-suppressing genetic material. By leveraging the naturally high GLUT1 activity in glioblastoma and innovatively coating lipid nanoparticles with mannose, the research delivers therapeutic mRNA encoding PTEN, restoring tumor inhibition and prolonging survival in preclinical models. This milestone could herald a new era of effective brain cancer treatments grounded in nanotechnology and molecular precision.

Subject of Research: Animals
Article Title: Single-ligand dual-targeting lipid nanoparticles for therapeutic mRNA delivery to glioblastoma across the blood-brain barrier
News Publication Date: 18-Jun-2026
Web References: http://dx.doi.org/10.1016/j.jconrel.2026.115107
References: Journal of Controlled Release
Image Credits: Parinaz Ghanbari
Keywords: glioblastoma, blood-brain barrier, lipid nanoparticles, mRNA therapy, PTEN, nanomedicine, GLUT1 transporter, mannose coating, targeted drug delivery, brain cancer, tumor suppression, nanotechnology

The funded initiative, formally titled “CNS penetrant inhibition of glucosylceramide synthase for the treatment of Gaucher disease and GM1 gangliosidosis,” zeroes in on addressing the neurological manifestations that remain intractable under current treatment modalities. Despite progress in therapies for peripheral symptoms, neuronopathic lysosomal storage disorders such as Gaucher disease type 3, GM1 gangliosidosis, Tay-Sachs, and Sandhoff disease largely elude treatment due to the impermeability of the blood-brain barrier (BBB) to existing drugs. This therapeutic development aspires to breach that barrier and deliver effective intervention within the central nervous system (CNS).

Dr. Shayman is renowned for inventing eliglustat tartrate, the first orally administered glucosylceramide synthase inhibitor approved worldwide for treating Gaucher disease type 1. Eliglustat functions by mitigating the pathological accumulation of glucosylceramide, a glycosphingolipid whose buildup initiates multi-organ damage in affected patients. However, the compound’s failure to cross the BBB renders it ineffective for neuronopathic forms of the disease, which affect the CNS and cause severe neurological decline.

Building upon decades of fundamental research in glycosphingolipid metabolism, Dr. Shayman teamed up with medicinal chemist Dr. Scott Larsen, also of the University of Michigan, to engineer a new generation of glucosylceramide synthase inhibitors capable of crossing the BBB. This collaboration yielded BPN-25271, a promising CNS-penetrant candidate compound that retains the pharmacodynamic attributes of eliglustat while adding brain accessibility. Early preclinical results have provided encouraging signals of therapeutic potential for this small molecule.

The C-Path BRIDGe grant will facilitate comprehensive preclinical evaluation of BPN-25271. Critical activities will include toxicology, pharmacokinetics, dose-ranging studies, and manufacturing optimization. These studies are prerequisites to submitting an Investigational New Drug (IND) application that would enable first-in-human clinical trials. The ultimate goal is to produce an effective disease-modifying therapy that halts or reverses neurological deterioration in patients afflicted with neuronopathic lysosomal storage disorders.

Dr. Shayman expressed the transformative potential of this research endeavor, emphasizing that “this funding enables us to take fundamental strides toward a therapy capable of addressing the unmet clinical needs of the CNS involvement in lysosomal storage diseases, conditions where currently clinicians can offer little beyond symptomatic care.” He highlighted that BPN-25271 represents an evolution built on the solid scientific framework established by prior discoveries in glucosylceramide biology.

The grant underscores the vital role of interdisciplinary collaboration and innovation in confronting rare, complex neurodegenerative diseases. Through initiatives like the BRIDGe program, C-Path advances translational research by strategically supporting early-stage projects with high potential to move rapidly toward clinical viability. Maaike Everts, Ph.D., Executive Director of C-Path’s Translational Therapeutics Accelerator, remarked that “this project embodies the exact kind of scientific rigor and translational promise that we aim to foster — combining molecular insights with medicinal chemistry to create novel therapeutic strategies capable of making a real difference for patients.”

Lysosomal storage disorders, particularly those with CNS involvement, represent a profound therapeutic challenge in rare disease medicine. These diseases result from enzyme deficiencies leading to substrate accumulation within lysosomes, disrupting cellular function especially in neural tissue. As traditional enzyme replacement therapies and substrate reduction therapies often do not reach the brain, novel approaches like brain-penetrant small molecule inhibitors are highly sought after.

This research initiative leverages contemporary advances in medicinal chemistry to optimize molecular features for enhanced blood-brain barrier permeability while preserving selectivity and potency against glucosylceramide synthase. Achieving this delicate balance is essential to maximizing CNS bioavailability without compromising safety or efficacy. Early-stage pharmacology data for BPN-25271 indicate promising pharmacokinetics and bio-distribution profiles supportive of this approach.

The support from C-Path not only accelerates drug development but also strengthens the global scientific network focused on rare neurodegenerative diseases. By connecting academic researchers, regulatory experts, and patient advocates, the institute creates a robust ecosystem that converts foundational science into tangible therapeutic options. This grant thus represents both a financial investment and a vote of confidence in the translational potential of BPN-25271.

If successful, this therapy would mark a watershed moment in treating neuronopathic forms of Gaucher disease and GM1 gangliosidosis, offering patients a much-needed option to slow or halt the progression of neurological symptoms. It may also set a precedent for treating other neurodegenerative lysosomal storage disorders characterized by glycolipid accumulation, thereby broadening the impact of this breakthrough approach.

In summary, the Critical Path Institute’s $456,000 grant to Dr. Shayman and colleagues is catalyzing the development of a next-generation CNS-penetrant glucosylceramide synthase inhibitor. This targeted approach seeks to overcome the formidable blood-brain barrier and tackle neurological disease manifestations that have, until now, been largely untreatable. The upcoming preclinical studies supported by this funding mark an important juncture on the path toward clinical translation and therapeutic innovation for patients suffering from devastating neuronopathic lysosomal storage disorders worldwide.

Subject of Research: Development of CNS-penetrant glucosylceramide synthase inhibitors for neuronopathic lysosomal storage disorders.

Article Title: Breakthrough Grant Spurs Development of Brain-Penetrant Therapy for Neuronopathic Lysosomal Storage Diseases

News Publication Date: April 28, 2026

Web References: https://c-path.org

Keywords: Lysosomal storage disorders, Gaucher disease type 3, GM1 gangliosidosis, glucosylceramide synthase, blood-brain barrier, CNS penetrant therapy, small molecule inhibitors, medicinal chemistry, rare neurodegenerative diseases, Critical Path Institute, enzyme inhibition, translational therapeutics

Ketamine, traditionally known as an anesthetic and recreational drug, has exhibited rapid antidepressant and anxiolytic effects at subanesthetic concentrations, transforming it into a molecule of great interest in neuropsychiatric research. However, conventional systemic delivery methods are often accompanied by side effects and limited targeting efficacy. The study introduces an innovative delivery mechanism via nanovesicles, engineered to encapsulate ketamine within specialized AmyloLipid-based carriers designed for intranasal administration. This biocompatible system enhances drug stability, bioavailability, and direct neural targeting, circumventing the blood-brain barrier challenges typical of many psychotropic agents.

The researchers utilized a rigorously validated animal model to simulate PTSD conditions, enabling them to meticulously assess the impacts of this novel delivery system on behavioral and physiological parameters. The model’s relevance lies in its capacity to reproduce core PTSD symptoms, including heightened anxiety, impaired fear extinction, and altered stress responsiveness, thereby providing a robust platform to test potential therapeutic interventions. Behavioral assays were complemented by advanced molecular analyses, offering a multifaceted perspective on treatment outcomes.

Intranasal administration of the ALN-encapsulated ketamine demonstrated remarkable improvements in anxiety-like behaviors and cognitive functions compared to control groups and those receiving untreated ketamine doses. These observations align with the drug’s known psychotropic profile but are notably enhanced by the precise delivery method, which promotes rapid absorption into olfactory and trigeminal pathways, ensuring swift central nervous system availability. This modality could herald a shift towards non-invasive, efficient, and patient-friendly administration routes for central nervous system disorders.

A vital aspect of the study was evaluating the neurobiological mechanisms underlying the ameliorated PTSD-like symptoms following treatment. The authors report significant modulation of synaptic plasticity markers and neuroinflammatory mediators within critical brain regions, including the amygdala and hippocampus, known to be pivotal in stress and fear processing. These molecular changes suggest that ALN-based ketamine delivery may restore the neural circuitry impaired by traumatic stress, offering insights into its therapeutic modus operandi.

Another groundbreaking element was the system’s ability to maintain subanesthetic ketamine levels, minimizing the risks of dissociative effects and potential abuse liability—major concerns limiting ketamine’s broader clinical use. The precision and sustained-release profile provided by the AmyloLipid nanovesicles offer a compelling balance of efficacy and safety. This highlights the potential for chronic therapeutic regimens without compromising patient compliance or well-being.

The implications of this research extend beyond PTSD, potentially influencing the treatment landscape of a spectrum of psychiatric disorders characterized by dysregulated glutamatergic transmission and neuroinflammation. The nanovesicular platform offers versatility not only in drug delivery but also in the possibility of co-encapsulating adjunctive therapeutic agents to tailor multifaceted treatment approaches. This could revolutionize personalized medicine paradigms in neuropsychiatry.

Moreover, this study underscores the critical importance of intranasal delivery routes in modern neuropharmacology. By exploiting the anatomical and physiological advantages of the nasal mucosa, therapeutics can bypass systemic metabolism and avoid first-pass effects, conditions that often diminish oral and intravenous drug efficacy. The utilization of AmyloLipid nanovesicles magnifies these advantages by adding structural robustness and facilitating controlled release kinetics.

This investigation also paves the way for deeper exploration into how nanoscale drug delivery technologies can modulate not just pharmacokinetics but also pharmacodynamics, especially in the delicate context of brain disorders where cellular heterogeneity and microenvironment complexity present formidable obstacles. The ALN-based intranasal system provides a sophisticated platform to interrogate and optimize drug-target interactions within neural tissue.

The researchers emphasize the translational potential of their findings, advocating for subsequent clinical trials to evaluate the safety, tolerability, and efficacy of intranasal ALN ketamine formulations in human PTSD patients. They also point toward the integration of neuroimaging and biomarker analyses in future studies to refine patient stratification and therapeutic monitoring. Such approaches could uniquely position this technology in the forefront of next-generation psychiatric therapies.

Importantly, the study’s methodological rigor, including the use of comprehensive behavioral phenotyping and cutting-edge molecular assays, lends credence to its conclusions and establishes a solid foundation for regulatory and clinical advancements. The interdisciplinary collaboration between neuroscientists, pharmacologists, and nanotechnologists exemplifies the integrative effort required to translate basic science innovations into viable medical interventions.

Furthermore, societal implications of this research are profound. PTSD is a leading cause of disability worldwide, affecting not only combat veterans but also survivors of various traumas including accidents, assaults, and disasters. A safe, effective, and easy-to-administer treatment modality can significantly alleviate healthcare burdens and improve quality of life for countless individuals, fostering broader mental health resilience.

As the field of nanomedicine continues to evolve, this study stands as a testament to the power of combining cutting-edge material science with neuroscience to tackle some of the most challenging mental health conditions of our time. It embodies a paradigm shift from symptomatic treatments to targeted, mechanism-based therapies designed to restore neural integrity and function.

With the advent of personalized molecular medicine, innovations such as the ALN-based subanesthetic ketamine delivery system offer a glimpse into a future where mental health disorders are no longer managed by trial and error but treated with precision, minimal side effects, and maximal efficacy. This transformative vision is well within reach, fueled by research at the intersection of nanotechnology and psychiatry.

In conclusion, Levy and colleagues’ 2026 study reports a milestone in PTSD treatment research, introducing an innovative, nanotechnology-driven intranasal ketamine delivery system that exerts potent biobehavioral impacts in animal models. This work integrates advances in pharmacology, materials science, and neurobiology, heralding a new era of therapies that promise to improve the lives of millions affected by trauma-induced psychiatric conditions. As clinical translation proceeds, hope glimmers for a future where PTSD and similar disorders are met with effective and compassionate treatment modalities grounded in technological and scientific ingenuity.

Subject of Research: Novel intranasal delivery of subanesthetic ketamine via AmyloLipid nanovesicles for PTSD treatment in animal models

Article Title: Impact of subanesthetic ketamine delivered via AmyloLipid nanovesicle (ALN)-based intranasal system on biobehavioral responses in an animal model of PTSD

Article References: Levy, G., Sintov, A.C., Zohar, J. et al. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03979-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03979-7